TITLE

Prescription dispensing costs above average in N.Y

AUTHOR(S)
R. A.
PUB. DATE
February 2007
SOURCE
Business Journal (Central New York);2/16/2007, Vol. 21 Issue 7, p16
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents information related to a survey which reports that the average cost of dispensing prescription medication in New York is $10.96 per prescription. This survey was conducted by the Coalition for Community Pharmacy Action (CCPA), an organization started by and representing the pharmacy and drug-store industry. The average cost of dispensing prescription medication in the U.S. is $10.50. Costs for dispensing prescriptions vary from state to state.
ACCESSION #
24112080

 

Related Articles

  • The Influence of Wholesale Discounts and Other Factors on Prescription Ingredient Costs. Gagnon, Jean P.; Rodowskas, Jr., Christopher A. // American Journal of Public Health;Oct1974, Vol. 64 Issue 10, p969 

    This study determines the actual prescription ingredient costs for sample prescriptions from a number of pharmacies and evaluates the relationships of annual prescription volume, source of purchase, drug wholesale monthly discounts, and chain warehouse costs on a prescription's ingredient cost.

  • Perspectives On The Pharmaceutical Industry. Reinhardt, Uwe E. // Health Affairs;2001 A Primer, p128 

    Characterizes the pharmaceutical industry in the United States. Cost structure of the industry; Effect of drug spending on the economy; Drug spending as a percentage of gross domestic product; Pharmaceutical profits as a source of cost containment; Cost sharing by patients; Price discrimination.

  • Do we pay too much for prescriptions?  // Consumer Reports;Oct93, Vol. 58 Issue 10, p668 

    Examines reasons why prescription drugs are priced highly. Pharmaceutical industry as first targets of health-care reform; Price raising during the 1980s; Profits earned by drug companies; Profits as necessary to attract capital for research and development; Price decisions as within the...

  • Gov't to delay drug price rises. Csonka, Agnes // Budapest Business Journal;06/10/2002, Vol. 10 Issue 27, p4 

    Reports on the Hungarian government's plan of delaying a proposed price increase in prescription drugs receiving state subsidies by six months. Price increase for National Health Fund Administration-subsidized medications by an average of 5 percent; Plans to hike the prices of over-the-counter...

  • Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes. Ioannides-Demos, L.L.; Ibrahim, J.E.; McNeil, J.J.; Ioannides-Demos, Lisa L; Ibrahim, Joseph E; McNeil, John J // PharmacoEconomics;2002, Vol. 20 Issue 9, p577 

    Pharmaceutical expenditure is rising more rapidly than the general inflation rate in most advanced countries. One strategy that has been introduced to control pharmaceutical costs is reference-based pricing (RBP). Its potential is restricted to those specific segments of the drug market where...

  • Prescription market booms with volume growth accelerating. Roller, Kim // Drug Store News;5/22/2000, Vol. 22 Issue 7, p51 

    Focuses on the retail drug prescription market in 1999 in the United States. Market share of chain drug stores; Increase in mail-order sales; Continued increase in prescription volume; Price increase for branded pharmaceuticals.

  • Nothing Sacred. Mulholland, Stephen // Finweek;4/28/2011, p21 

    In this article the author highlights the underlying factors that add to the cost of production and the total cost of a marketable branded drug manufactured by pharmaceutical companies like research and development, shareholders interests in the form of dividends. For an average hypochondriac in...

  • Drug companies face pressure on profits. Josefson, Deborah // BMJ: British Medical Journal (International Edition);1/12/2002, Vol. 324 Issue 7329, p65 

    Reports on pressure related to profits facing major pharmaceutical corporations in the United States. Expected impact on drug companies such as Merck, Bristol-Myers Squibb, Eli Lilly, Schering-Plough, and Pharmacia; Impact on popular prescription brand name drugs and their generic equivalents;...

  • E&Y Division Launching Program To Help Health Plans Manage Prescription Expenses.  // Insurance Advocate;4/8/2002, Vol. 113 Issue 13, p38 

    Announces the launch of the RxManager service from Ernst & Young LLP, to help health plans manage prescription expenses on March 25, 2002.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics